Articles from PHC Holdings Corporation
Epredia, a global leader in precision cancer diagnostics and a subsidiary of PHC Holdings Corporation (TSE: 6523), and Mindpeak, a leading provider of artificial intelligence (AI) solutions for clinical and research pathology, today announced a distribution agreement to bring Mindpeak’s AI-based image recognition software to Epredia’s digital pathology customers in the European Union.
By PHC Holdings Corporation · Via Business Wire · February 24, 2026
PHC Holdings Corporation (President, Representative Director and CEO: Kyoko Deguchi, TSE: 6523) and its subsidiary Ascensia Diabetes Care, a global diabetes care company, today announced that Ascensia has signed a memorandum of understanding to transfer the commercial operations for Eversense® Continuous Glucose Monitoring (CGM) systems to Eversense maker Senseonics Holdings, Inc. (NYSE American: SENS). The companies are targeting to unite Eversense R&D, manufacturing, and commercial activities within Senseonics beginning January 1, 2026, subject to a definitive agreement.
By PHC Holdings Corporation · Via Business Wire · September 3, 2025

PHC Holdings Corporation (TSE:6523) (hereafter PHCHD), the parent company of Ascensia Diabetes Care, a global diabetes care company, along with Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that diabetes industry veteran Brian Hansen has been appointed to the newly created role of President of CGM at Ascensia Diabetes Care, effective February 6, 2024. Ascensia is the exclusive global distributor of the Eversense® E3 CGM system developed and manufactured by Senseonics.
By PHC HOLDINGS CORPORATION · Via Business Wire · February 6, 2024

PHC Holdings Corporation (headquarters: Minato-ku, Tokyo, Japan, President & CEO: Shoji Miyazaki, hereafter PHC Group) announces the release of its newly revised Mid-term Plan, the “Value Creation Plan”*1 for FY2022 to FY2025. The primary update in this plan is the introduction of new business growth areas that will enable PHC Group to advance value-based healthcare globally.
By PHC Holdings Corporation · Via Business Wire · November 16, 2022

PHC Holdings Corporation (hereafter PHC Group) (TOKYO:6523) today announced the appointment of Shoji Miyazaki as the company’s Chief Executive Officer. He succeeds John Marotta, who has stepped down as the company’s CEO and Representative Director and also from the Board of Directors effective April 28, 2022. Shoji Miyazaki remains a Representative Director on the company’s Board of Directors.
By PHC Holdings Corporation · Via Business Wire · April 28, 2022

PHC Holdings Corporation (headquarters: Minato-ku, Tokyo, Japan, President & CEO: John Marotta, hereafter PHCHD), a leading global life science, diagnostics and medical device company, has today announced the appointment of William (Bill) Donnelly and Ivan Tornos as independent external directors, effective September 3, 2021. Both bring significant expertise and executive-level experience at global medical device and life sciences companies.
By PHC Holdings Corporation · Via Business Wire · September 3, 2021

PHC Holdings Corporation (headquarters: Minato-ku, Tokyo, Japan, President & CEO: John Marotta, hereafter PHCHD), a leading global healthcare company, has today announced the appointment of Alan Malus and Kyoko (Kay) Deguchi as independent external directors, effective June 30, 2021. Both bring extensive knowledge of the healthcare industry and executive-level experience at international and Japan-based medical device and life sciences companies.
By PHC Holdings Corporation · Via Business Wire · July 28, 2021
